CRBP Corbus Pharmaceuticals Holdings, Inc. Stock Quote

CRBP [NASD]

Corbus Pharmaceuticals Holdings, Inc.

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	0.50%	Shs Outstand	81.88M	Perf Week	21.26%
Market Cap	198.30M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-29.26%	Shs Float	77.47M	Perf Month	38.82%
Income	-129.20M	PEG	-	EPS next Q	-0.25	Inst Own	57.10%	Short Float	20.86%	Perf Quarter	124.18%
Sales	5.90M	P/S	33.61	EPS this Y	-14.50%	Inst Trans	-17.05%	Short Ratio	2.48	Perf Half Y	-68.97%
Book/sh	0.36	P/B	5.86	EPS next Y	54.70%	ROA	-167.70%	Target Price	1.88	Perf Year	-69.94%
Cash/sh	0.87	P/C	2.42	EPS next 5Y	-	ROE	-485.50%	52W Range	0.91 - 9.78	Perf YTD	68.80%
Dividend	-	P/FCF	-	EPS past 5Y	-61.90%	ROI	-	52W High	-78.43%	Beta	2.19
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	-	Gross Margin	-	52W Low	131.87%	ATR	0.18
Employees	141	Current Ratio	2.10	Sales Q/Q	-53.80%	Oper. Margin	-	RSI (14)	70.22	Volatility	15.04% 10.14%
Optionable	Yes	Debt/Eq	0.61	EPS Q/Q	-32.50%	Profit Margin	-	Rel Volume	1.97	Prev Close	2.36
Shortable	Yes	LT Debt/Eq	0.61	Earnings	Nov 10 BMO	Payout	-	Avg Volume	6.53M	Price	2.11
Recom	2.80	SMA20	39.87%	SMA50	52.21%	SMA200	-52.66%	Volume	12,867,700	Change	-10.59%

Sep-08-20

Downgrade

ROTH Capital

Buy → Neutral

$40 → $3

Sep-08-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Sep-08-20

Downgrade

Jefferies

Buy → Hold

$18 → $2.50

Sep-08-20

Downgrade

BTIG Research

Buy → Neutral

Jul-07-20

Initiated

ROTH Capital

Buy

$40

Jun-17-20

Initiated

BTIG Research

Buy

$22

Mar-26-20

Initiated

Nomura

Buy

$12

Apr-05-19

Initiated

Jefferies

Buy

Mar-20-19

Initiated

Oppenheimer

Outperform

$28

Jan-11-19

Reiterated

Cantor Fitzgerald

Overweight

$36 → $38

Dec-26-18

Initiated

H.C. Wainwright

Buy

$24

Dec-07-18

Initiated

RBC Capital Mkts

Outperform

$23

Oct-24-18

Initiated

B. Riley FBR

Buy

$22

Jan-19-18

Initiated

Raymond James

Outperform

$24

Dec-14-17

Reiterated

Cantor Fitzgerald

Overweight

$24 → $28

Nov-08-17

Reiterated

Noble Financial

Buy

$16 → $20

Sep-29-17

Resumed

Noble Financial

Buy

$16

Mar-30-17

Reiterated

Cantor Fitzgerald

Overweight

$17 → $24

Nov-15-16

Reiterated

JMP Securities

Mkt Outperform

$9 → $20

Nov-11-16

Reiterated

Noble Financial

Buy

$19

Jan-20-21 08:05AM	Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases GlobeNewswire
Jan-14-21 08:30AM	Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3% Zacks +8.07%
Jan-12-21 08:49AM	Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options Zacks
Jan-09-21 02:16AM	A Look At Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Share Price Returns Simply Wall St.
Dec-07-20 10:43PM	Is CRBP A Good Stock To Buy Now? Insider Monkey
Dec-04-20 08:44AM	Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock? Zacks +6.77%
Dec-01-20 10:28AM	Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga +18.85%
Nov-16-20 09:54AM	ROCE Insights For Corbus Pharmaceuticals Benzinga
Nov-12-20 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +13.11%
Nov-11-20 10:00AM	Corbus Pharma Drops 6% On 3Q Miss; Street Sees 79% Upside SmarterAnalyst
Nov-10-20 03:31PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q3 2020 Earnings Call Transcript Motley Fool
08:55AM	Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:32AM	Corbus Pharmaceuticals: Q3 Earnings Insights Benzinga
07:05AM	Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates GlobeNewswire
Nov-09-20 10:27AM	Corbus Pharmaceuticals's Earnings: A Preview Benzinga +7.96%
08:05AM	Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis GlobeNewswire
Nov-03-20 08:05AM	Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020 GlobeNewswire
Oct-29-20 12:35PM	Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-23-20 08:05AM	Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020 GlobeNewswire
Oct-21-20 08:05AM	Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020 GlobeNewswire
Oct-08-20 08:05AM	Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates GlobeNewswire
Oct-07-20 10:46AM	Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint Zacks
Oct-06-20 07:05AM	Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint GlobeNewswire -35.98%
Oct-04-20 09:46AM	How Much Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Do Institutions Own? Simply Wall St.
Sep-25-20 08:53AM	Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock? Zacks
Sep-24-20 09:54AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Sep-10-20 10:01AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga -6.97%
Sep-08-20 10:00AM	Why Corbus Pharmaceuticals Is Getting Slammed Today Motley Fool -75.89%
07:05AM	Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis GlobeNewswire
Sep-04-20 09:40AM	Understanding Corbus Pharmaceuticals's Unusual Options Activity Benzinga
Aug-25-20 09:19AM	Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options Zacks
Aug-24-20 06:30AM	2 Dirt-Cheap Robinhood Stocks That Could Skyrocket Motley Fool
Aug-20-20 10:17AM	Are Insiders Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock? Simply Wall St. +5.45%
Aug-16-20 08:15AM	3 Stocks Robinhood Investors Love Motley Fool
Aug-14-20 10:31AM	Looking Into Corbus Pharmaceuticals's Return On Capital Employed Benzinga
Aug-06-20 07:05AM	Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates GlobeNewswire -11.47%
Aug-05-20 09:25AM	Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis GlobeNewswire
Aug-03-20 08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire +8.29%
Jul-30-20 08:05AM	Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020 GlobeNewswire
Jul-29-20 08:05AM	Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital GlobeNewswire -6.26%
Jul-21-20 10:02AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Jul-17-20 04:21PM	Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals Motley Fool
Jul-15-20 02:38PM	What Does Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) CEO Pay Reveal? Simply Wall St.
Jul-08-20 08:05AM	Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors GlobeNewswire
Jul-05-20 09:58PM	Corbus Pharmaceuticals Holdings Inc (CRBP): Are Hedge Funds Right About This Stock? Insider Monkey
Jun-29-20 08:05AM	Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress GlobeNewswire
Jun-22-20 08:05AM	Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis GlobeNewswire
Jun-18-20 10:56AM	2 Strong Buy Small-Cap Stocks That Could See Outsized Gains TipRanks
08:51AM	Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Jun-01-20 09:00AM	Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now? Zacks
08:05AM	Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis GlobeNewswire
May-28-20 06:53AM	Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely? Simply Wall St.
May-27-20 08:05AM	Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis GlobeNewswire
May-22-20 08:05AM	Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress GlobeNewswire +5.22%
May-18-20 03:09AM	Edited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-15-20 12:00PM	Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade Zacks +5.53%
08:05AM	Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
May-14-20 09:30AM	Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't? Zacks
May-11-20 09:55AM	Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:05AM	Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates GlobeNewswire
May-04-20 08:05AM	Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020 GlobeNewswire +7.97%
Apr-30-20 04:15PM	Viela Bio Announces Election of Rachelle Jacques to its Board of Directors GlobeNewswire
Apr-29-20 08:05AM	Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology GlobeNewswire
Apr-28-20 07:05AM	Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Shareholders Booked A 86% Gain In The Last Five Years Simply Wall St.
Apr-02-20 08:58AM	Implied Volatility Surging for Corbus (CRBP) Stock Options Zacks
04:00AM	Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-14-20 08:52AM	Corbus Pharmaceuticals Holdings, Inc. Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
Mar-12-20 08:55AM	Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates Zacks -7.52%
07:05AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
06:30AM	Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-20 08:05AM	Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director GlobeNewswire +8.59%
07:14AM	Did Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Insiders Buy Up More Shares? Simply Wall St.
Mar-05-20 08:05AM	Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020 GlobeNewswire -5.87%
Mar-03-20 12:30PM	Earnings Preview: Corbus Pharmaceuticals (CRBP) Q4 Earnings Expected to Decline Zacks
Feb-11-20 04:01PM	Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Feb-10-20 08:58AM	Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock? Zacks
Feb-07-20 09:02AM	Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -7.87%
Feb-06-20 04:01PM	Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-31-20 03:45PM	Top Marijuana Stocks on the NASDAQ Investopedia
Jan-25-20 08:09AM	Is Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) A Volatile Stock? Simply Wall St.
Dec-19-19 08:07AM	Does Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Pay Matter? Simply Wall St.
Dec-17-19 04:07PM	Hedge Funds Are Selling Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Monkey
Dec-09-19 08:05AM	Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System GlobeNewswire
Nov-18-19 08:17AM	Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis GlobeNewswire
Nov-16-19 09:40PM	Edited Transcript of CRBP earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 08:05AM	Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London GlobeNewswire
07:20AM	We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business Growth Simply Wall St.
Nov-11-19 08:05AM	Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting GlobeNewswire
Nov-07-19 11:15AM	Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Tops Revenue Estimates Zacks -7.96%
07:05AM	Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates GlobeNewswire
Nov-05-19 01:00PM	3 Under-the-Radar Stocks Top Insiders Are Snapping Up TipRanks
Nov-04-19 08:05AM	Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019 GlobeNewswire
Nov-01-19 12:08PM	Were Hedge Funds Right About Selling Corbus Pharmaceuticals (CRBP)? Insider Monkey
Oct-13-19 10:06AM	What Percentage Of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Do Insiders Own? Simply Wall St.
Oct-03-19 08:05AM	Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting GlobeNewswire
Oct-01-19 09:03AM	Marijuana stocks are oversold heres how to know when to buy them MarketWatch
Sep-13-19 07:21AM	Health Check: How Prudently Does Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Use Debt? Simply Wall St.
Aug-16-19 12:00AM	Edited Transcript of CRBP earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 08:32AM	Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year? Simply Wall St. -6.07%
01:35AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP) Q2 2019 Earnings Call Transcript Motley Fool

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moran Sean F.	Chief Financial Officer	Dec 21	Option Exercise	1.40	87,500	122,500	437,110	Dec 22 04:42 PM
Moran Sean F.	Chief Financial Officer	Dec 21	Sale	1.75	87,500	153,125	349,610	Dec 22 04:42 PM
Moran Sean F.	Chief Financial Officer	Dec 18	Option Exercise	1.00	53,610	53,610	403,220	Dec 22 04:42 PM
Moran Sean F.	Chief Financial Officer	Dec 18	Sale	1.40	53,610	75,054	349,610	Dec 22 04:42 PM
Moran Sean F.	Chief Financial Officer	Dec 16	Option Exercise	0.17	36,923	6,118	386,533	Dec 18 04:44 PM
Moran Sean F.	Chief Financial Officer	Dec 16	Sale	1.32	36,923	48,628	349,610	Dec 18 04:44 PM
Cohen Yuval	Chief Executive Officer	Nov 11	Buy	1.21	4,240	5,126	75,330	Nov 12 10:28 AM
Millian Craig Stuart	Chief Commercial Officer	Mar 17	Buy	4.25	2,000	8,500	12,000	Mar 18 01:18 PM
Cohen Yuval	Chief Executive Officer	Mar 17	Buy	3.49	4,300	15,007	71,090	Mar 17 01:14 PM
Discordia Robert Paul	Chief Operating Officer	Mar 17	Buy	3.54	2,840	10,054	35,490	Mar 18 11:21 AM
White Barbara	Chief Medical Officer	Mar 17	Buy	3.63	15,606	56,650	206,217	Mar 18 10:37 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience